Such an Opportunity May Never Come Again
The quality of projects developed in Polish laboratories is already appreciated by global giants. This is a unique opportunity for a win-win strategy between the Polish biotech sector and foreign investors
2022 was a landmark year for the Polish life sciences sector. The first drug developed in Polish laboratories was approved for the US market, and our scientific prowess was recognised by major international industry players, including BioNTech, Bio-Rad and Qiagen. Cash proceeds from the sale or licensing of Polish biotechnology innovations exceeded 1 billion PLN ‒ much more than total historical earnings combined.
Bądź na bieżąco ze zmianami w prawie i podatkach.
Czytaj raporty, analizy i wyjaśnienia ekspertów.
Bądź na bieżąco ze zmianami w prawie i podatkach.
Czytaj raporty, analizy i wyjaśnienia ekspertów.
Materiał chroniony prawem autorskim - wszelkie prawa zastrzeżone.
Dalsze rozpowszechnianie artykułu za zgodą wydawcy INFOR PL S.A. Kup licencję.